Epithelial ovarian cancer (OC) is the leading cause of cancer-related deaths in women worldwide: It is estimated that in 2018, the number of deaths due to OC worldwide was close to 185,000 .
Standard treatments for advanced ovarian cancer include cytoreductive surgery and platinum-taxane combination chemotherapy.
This study aims to evaluate the addition of human monoclonal anti-PD-L1 antibody atezolizumab to the platinum-based combination with bevacizumab for newly diagnosed stage III-IV Efficacy of ovarian cancer .
This is a multicenter, placebo-controlled, randomized, double-blind phase III trial that recruited newly diagnosed patients with stage III-IV ovarian cancer who had undergone primary tumor cytoreduction or planned to undergo Neoadjuvant chemotherapy and interval surgery.
The test patients were randomly divided into two groups 1:1, and received atuzumab (1200 mg) or placebo in addition to standard chemotherapy (paclitaxel + cisplatin + bevacizumab).
The primary endpoints are progression-free survival and overall survival.
PFS and OS in the intention-to-treat population and PD-L1 positive populationPFS and OS in the intention-to-treat population and PD-L1 positive population
From March 8, 2017 to March 26, 2019, a total of 1301 patients were recruited.
In the intention-to-treat population, the median progression-free survival of the atuzumab group and placebo group was 19.
5 months vs 18.
4 months (hazard ratio [HR] 0.
92, 95%CI 0.
5 months vs 18.
4 months, respectively
PFS in PD-L1 positive subgroupPFS in PD-L1 positive subgroup
Among PD-L1 positive patients, the median progression-free survival of the atuzumab group and placebo group was 20.
8 months vs.
5 months (HR 0.
80, 95%CI 0.
The results of the mid-term overall survival analysis showed that atuzumab had no obvious survival benefit.
8 months vs 18.
5 months, respectively
The most common grade 3-4 adverse events were neutropenia (atuzumab group vs placebo group: 21% vs 21%), hypertension (18% vs 20%), and anemia (12% vs.
In summary, the current analysis results of the study do not support the use of immune checkpoint inhibitors for newly diagnosed ovarian cancer patients .
Original source:Original source:
Moore, et al.
00306" target="_blank" rel="noopener">Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) .
J Clin Oncol.
April 23, 2021 .
00306" target="_blank" rel="noopener">Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050 / GOG 3015 / ENGOT-OV39)
in this message